CoChat

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

Open access
ten Kate, Mara, Redolfi, Alberto, Peira, Enrico, Bos, Isabelle, Vos, Stephanie J., Vandenberghe, Rik, Gabel, Silvy, Schaeverbeke, Jolien, Scheltens, Philip, Blin, Olivier, Richardson, Jill C., Bordet, Regis, Wallin, Anders, Eckerstrom, Carl, Molinuevo, José Luis, Engelborghs, Sebastiaan, Van Broeckhoven, Christine, Martinez-Lage, Pablo, Popp, Julius, Tsolaki, Magdalini, Verhey, Frans R. J., Baird, Alison L., Legido-Quigley, Cristina, Bertram, Lars, Dobricic, Valerija, Zetterberg, Henrik, Lovestone, Simon, Streffer, Johannes, Bianchetti, Silvia, Novak, Gerald P., Revillard, Jerome, Gordon, Mark F., Xie, Zhiyong, Wottschel, Viktor, Frisoni, Giovanni, Visser, Pieter Jelle, Barkhof, Frederik · 2018 · Alzheimer's Research & Therapy

Abstract

BACKGROUND: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict amyloid pathology. The aim of this study was to assess whether easily obtainable measures from structural MRI, combined with demographic data, cognitive data and apolipoprotein E (APOE) ε4 genotype, can be used to predict amyloid pathology using machine-learning classification. METHODS: We examined 810 subjects with structural MRI data and amyloid markers from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, including subjects with normal cognition (CN, n = 337, age 66.5 ± 7.2, 50% female, 27% amyloid positive), mild cognitive impairment (MCI, n = 375, age 69.1 ± 7.5, 53% female, 63% amyloid positive) and AD dementia (n = 98, age 67.0 ± 7.7, 48% female, 97% amyloid positive). Structural MRI scans were visually assessed and Freesurfer was used to obtain subcortical volumes, cortical thickness and surface area measures. We first assessed univariate associations between MRI measures and amyloid pathology using mixed models. Next, we developed and tested an automated classifier using demographic, cognitive, MRI and APOE ε4 information to predict amyloid pathology. A support vector machine (SVM) with nested 10-fold cross-validation was applied to identify a set of markers best discriminating between amyloid positive and amyloid negative subjects. RESULTS: In univariate associations, amyloid pathology was associated with lower subcortical volumes and thinner cortex in AD-signature regions in CN and MCI. The multi-variable SVM classifier provided an area under the curve (AUC) of 0.81 ± 0.07 in MCI and an AUC of 0.74 ± 0.08 in CN. In CN, selected features for the classifier included APOE ε4, age, memory scores and several MRI measures such as hippocampus, amygdala and accumbens volumes and cortical thickness in temporal and parahippocampal regions. In MCI, the classifier including demographic and APOE ε4 information did not improve after additionally adding imaging measures. CONCLUSIONS: Amyloid pathology is associated with changes in structural MRI measures in CN and MCI. An automated classifier based on clinical, imaging and APOE ε4 data can identify the presence of amyloid pathology with a moderate level of accuracy. These results could be used in clinical trials to pre-screen subjects for anti-amyloid therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-018-0428-1

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Number of included subjects. EMIF-AD MBD European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery, MRI magnetic resonance imaging
Fig. 1 Number of included subjects. EMIF-AD MBD European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery, MRI magnetic resonance imagingCC BY · PubMed Central
Fig. 2 Freesurfer regions selected as features for the classifier in cognitively normal (top row) and mild cognitive impairment (bottom row). Colour bars represent averaged feature weight
Fig. 2 Freesurfer regions selected as features for the classifier in cognitively normal (top row) and mild cognitive impairment (bottom row). Colour bars represent averaged feature weightCC BY · PubMed Central
Fig. 3 Classifier results. Receiver operating characteristic (ROC) curves of support vector machine classifier to predict amyloid pathology in cognitively normal (left panel) and mild cognitive impairment (right panel) subjects. Red: results from the combined classifier, including demographic information, neuropsychological tests, MRI measures and APOE ε4 genotype. Specific features selected presented in Additional file 1: Table S8. Classifier results from demographic information combined with only neuropsychology (green), or MRI measures (blue) or APOE ε4 genotype (yellow). ROC significant differences assessed with DeLong’s test. *p < 0.05, **p < 0.001, ns not significant. APOE, apolipoprotein E, MRI magnetic resonance imaging
Fig. 3 Classifier results. Receiver operating characteristic (ROC) curves of support vector machine classifier to predict amyloid pathology in cognitively normal (left panel) and mild cognitive impairment (right panel) subjects. Red: results from the combined classifier, including demographic information, neuropsychological tests, MRI measures and APOE ε4 genotype. Specific features selected presented in Additional file 1: Table S8. Classifier results from demographic information combined with only neuropsychology (green), or MRI measures (blue) or APOE ε4 genotype (yellow). ROC significant differences assessed with DeLong’s test. *p < 0.05, **p < 0.001, ns not significant. APOE, apolipoprotein E, MRI magnetic resonance imagingCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 80

Metadata

Authors
ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S. J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., Richardson, J. C., Bordet, R., Wallin, A., Eckerstrom, C., Molinuevo, J. L., Engelborghs, S., Van Broeckhoven, C., Martinez-Lage, P., Popp, J., Tsolaki, M., Verhey, F. R. J., Baird, A. L., Legido-Quigley, C., Bertram, L., Dobricic, V., Zetterberg, H., Lovestone, S., Streffer, J., Bianchetti, S., Novak, G. P., Revillard, J., Gordon, M. F., Xie, Z., Wottschel, V., Frisoni, G., Visser, P. J., & Barkhof, F.
Affiliations
  • Centro San Giovanni di Dio Fatebenefratelli (IT)
  • Maastricht University (NL)
  • Universitair Ziekenhuis Leuven (BE)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Assistance Publique Hôpitaux de Marseille (FR)
  • GlaxoSmithKline (United Kingdom) (GB)
  • University of Gothenburg (SE)
  • University of Antwerp (BE)
  • Centre Hospitalier Universitaire Vaudois (CH)
  • University of Oxford (GB)
  • University of Oslo (NO)
  • Sahlgrenska University Hospital (SE)
  • Teva Pharmaceuticals (United States) (US)
  • Pfizer (United States) (US)
  • University of Geneva (CH)
  • University College London (GB)
Venue
Alzheimer's Research & Therapy
Published
2018-09-27
Volume
10
Issue
1
Pages
100-100
ISSN
1758-9193 (ISSN-L)
OpenAlex
W2894000069
Cited by
78
References
52
Citations by year
2026: 4 · 2025: 8 · 2024: 14 · 2023: 9 · 2022: 12 · 2021: 14 · 2020: 7 · 2019: 10
FWCI
6.10
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • IRIS (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
  • SERVAL (Université de Lausanne) (submittedVersion, other-oa)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
Innovative Medicines Initiative Joint Undertaking (EMIF grant: 115372)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
amyloid pathology, Alzheimer's disease, structural MRI, amyloid biomarkers, mild cognitive impairment, pre-dementia, APOE ε4, subcortical volume, cortical thickness, hippocampus, amygdala, accumbens, support vector classifier, multimodal biomarkers, non-invasive prediction, machine learning classification
MeSH terms
Aged, Alzheimer Disease, Brain, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, ROC Curve, Biomarkers, Amyloid beta-Peptides, Apolipoprotein E4, Support Vector Machine, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. https://app.cochat.ai/papers/10.1186/s13195-018-0428-1
The paper
ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S. J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., Richardson, J. C., Bordet, R., Wallin, A., Eckerstrom, C., Molinuevo, J. L., Engelborghs, S., Van Broeckhoven, C., Martinez-Lage, P., Popp, J., . . . Barkhof, F. (2018). MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-018-0428-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.